Vera Therapeutics Inc Cl A (VERA)

$41.20 -1.46 (-3.42%)
Market Cap 2.96B
Revenue (ttm) 0.00
Net Income (ttm) -299.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 5,143,900
Avg Vol 1,401,266
Day's Range N/A - N/A
Shares Out 71.78M
Stochastic %K 59%
Beta 0.92
Analysts Strong Sell
Price Target $78.00

Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 770 0077
Website: veratx.com
Address:
2000 Sierra Point Parkway, Suite 1200, Brisbane, United States
flamingojack
flamingojack Jul. 4 at 12:57 PM
$VERA Claude, Gemini, Grok, and ChatGPT all state we’re setup for a squeeze.
1 · Reply
The_Beginner
The_Beginner Jul. 3 at 8:54 PM
$VERA how come there is not more excitment here with fda result the coming week?
3 · Reply
Oscarca
Oscarca Jul. 3 at 6:13 PM
$CELC It’s going to be one exciting July with both $CELC and $VERA
0 · Reply
Oscarca
Oscarca Jul. 3 at 5:09 PM
$VERA Double fireworks Vera and 4th of July 🚀
0 · Reply
flamingojack
flamingojack Jul. 3 at 4:54 PM
$VERA options data pulled from the last trading session.
0 · Reply
flamingojack
flamingojack Jul. 3 at 4:29 PM
$VERA lots of good stuff in this article. Very excited for the future of atacicept (and my portfolio) https://finance.yahoo.com/healthcare/articles/fda-progress-could-send-biotech-134034059.html?.tsrc=ios&guccounter=1
0 · Reply
treadingw4ter
treadingw4ter Jul. 2 at 9:03 PM
$VERA Last PDUFA I held through was GRCE. Having flashbacks. Worth trimming into strength on this, or do we have 𝘵𝘩𝘢𝘵 much conviction?
2 · Reply
RandomInvestor777
RandomInvestor777 Jul. 2 at 8:25 PM
$VERA btw wasn't PIONEER data supposed to be out by now? they said Q2...
1 · Reply
oneg
oneg Jul. 2 at 8:13 PM
$VERA Only two working days left before the final decision.
2 · Reply
Xavier75
Xavier75 Jul. 2 at 7:48 PM
$VERA
0 · Reply
Latest News on VERA
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2026, 4:05 PM EDT - 4 weeks ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

2026-06-02T16:27:12.000Z - 4 weeks ago

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis

Raymond James sees unique buying opportunity in Vera after FDA alignment

2026-06-02T16:26:20.000Z - 4 weeks ago

Raymond James sees unique buying opportunity in Vera after FDA alignment

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Jun 2, 2026, 7:00 AM EDT - 4 weeks ago

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics Transcript: AGM 2026

May 21, 2026, 11:00 AM EDT - 6 weeks ago

Vera Therapeutics Transcript: AGM 2026

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI

2026-05-15T12:28:46.000Z - 7 weeks ago

Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI

Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)

2026-05-07T20:08:52.000Z - 2 months ago

Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:30 AM EDT - 2 months ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

Vera Therapeutics Earnings release: Q1 2026

Vera Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

Vera Therapeutics Quarterly report: Q1 2026

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

May 4, 2026, 7:30 AM EDT - 2 months ago

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Vera Therapeutics Proxy statement: Proxy filing

Vera Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Vera Therapeutics Proxy statement: Proxy filing

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Mar 25, 2026, 7:30 AM EDT - 3 months ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

2026-03-10T23:05:13.000Z - 4 months ago

Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

VRTX

Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA

2026-03-10T12:03:07.000Z - 4 months ago

Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA

VRTX

Vera Therapeutics appoints Hite to Board of Directors

2026-03-05T14:16:31.000Z - 4 months ago

Vera Therapeutics appoints Hite to Board of Directors

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Mar 5, 2026, 9:00 AM EST - 4 months ago

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 4 months ago

Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

2026-03-02T11:11:41.000Z - 4 months ago

Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright

Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)

2026-02-26T12:46:30.000Z - 4 months ago

Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)

Vera Therapeutics sees cash runway through atacicept commercial launch

2026-02-26T12:46:00.000Z - 4 months ago

Vera Therapeutics sees cash runway through atacicept commercial launch

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Feb 26, 2026, 7:30 AM EST - 4 months ago

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Vera Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:30 AM EST - 4 months ago

Vera Therapeutics Annual report: Q4 2025

Vera Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:30 AM EST - 4 months ago

Vera Therapeutics Earnings release: Q4 2025

Vera Therapeutics to Participate at Upcoming Investor Conferences

Feb 24, 2026, 8:00 AM EST - 4 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics appoints Skelton as Chief Commercial Officer

2026-01-28T12:35:58.000Z - 5 months ago

Vera Therapeutics appoints Skelton as Chief Commercial Officer

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Jan 28, 2026, 7:30 AM EST - 5 months ago

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Vera Therapeutics Slides: Corporate presentation

Jan 28, 2026, 7:00 AM EST - 5 months ago

Vera Therapeutics Slides: Corporate presentation

Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 6 months ago

Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 6 months ago

Vera Therapeutics Slides: Corporate presentation

Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA

2026-01-07T12:37:21.000Z - 6 months ago

Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Jan 7, 2026, 7:30 AM EST - 6 months ago

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Wells Fargo sees short squeeze ahead: here are three stocks to play it

Jan 6, 2026, 2:31 PM EST - 6 months ago

Wells Fargo sees short squeeze ahead: here are three stocks to play it

HRI MTDR

Short Report: Vera Therapeutics bears retreat as stock rallies

2025-12-21T23:50:11.000Z - 6 months ago

Short Report: Vera Therapeutics bears retreat as stock rallies

MBLY MDGL NGNE

Vera Therapeutics price target raised to $66 from $48 at BofA

2025-12-19T12:35:35.000Z - 7 months ago

Vera Therapeutics price target raised to $66 from $48 at BofA

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

2025-12-19T12:25:27.000Z - 7 months ago

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

Vera Therapeutics price target lowered to $96 from $99 at JPMorgan

2025-12-19T12:00:44.000Z - 7 months ago

Vera Therapeutics price target lowered to $96 from $99 at JPMorgan

Vera Therapeutics director buys $250K in common stock

2025-12-16T01:50:18.000Z - 7 months ago

Vera Therapeutics director buys $250K in common stock

Vera Therapeutics price target raised to $33 from $23 at Wedbush

2025-12-11T13:26:34.000Z - 7 months ago

Vera Therapeutics price target raised to $33 from $23 at Wedbush

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Dec 9, 2025, 8:57 PM EST - 7 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Dec 8, 2025, 4:01 PM EST - 7 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 4:00 PM EST - 7 months ago

Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:45 AM EST - 7 months ago

Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Nov 26, 2025, 4:05 PM EST - 7 months ago

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 13, 2025, 1:30 PM EST - 8 months ago

Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Nov 10, 2025, 7:29 AM EST - 8 months ago

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Nov 7, 2025, 6:27 PM EST - 8 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Vera Therapeutics Transcript: KOL Event

Nov 6, 2025, 4:30 PM EST - 8 months ago

Vera Therapeutics Transcript: KOL Event

Vera Therapeutics Press release: KOL Event

Nov 6, 2025, 4:30 PM EST - 8 months ago

Vera Therapeutics Press release: KOL Event

Vera Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 4:30 PM EST - 8 months ago

Vera Therapeutics Slides: Corporate Presentation

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Nov 6, 2025, 9:51 AM EST - 8 months ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 7:29 AM EST - 8 months ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Vera Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Vera Therapeutics Earnings release: Q3 2025

Vera Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Vera Therapeutics Quarterly report: Q3 2025

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Oct 17, 2025, 9:12 AM EDT - 9 months ago

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:10 AM EDT - 10 months ago

Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Vera Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 12:30 PM EDT - 11 months ago

Vera Therapeutics Quarterly report: Q2 2025

Vera Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 12:30 PM EDT - 11 months ago

Vera Therapeutics Earnings release: Q2 2025

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 7:05 PM EDT - 1 year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 3:15 PM EDT - 1 year ago

Vera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 1 year ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Jun 3, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Vera Therapeutics Transcript: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Vera Therapeutics Press release: Study Result

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Press release: Study Result

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Vera Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Quarterly report: Q1 2025

Vera Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Earnings release: Q1 2025

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

Vera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:25 AM EST - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vera Therapeutics Annual report: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics Annual report: Q4 2024

Vera Therapeutics Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics Earnings release: Q4 2024

Vera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Vera Therapeutics Slides: FY 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Slides: FY 2025

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 5, 2024, 7:55 AM EST - 1 year ago

Vera Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Vera Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 9:30 AM EST - 1 year ago

Vera Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Vera Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics Quarterly report: Q3 2024

Vera Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics Earnings release: Q3 2024

Vera Therapeutics Transcript: Study Result

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Vera Therapeutics Slides: Study Result

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Slides: Study Result

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 26, 2024, 7:30 PM EDT - 1 year ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Transcript: R&D Day 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: R&D Day 2024

Vera Therapeutics Slides: FY 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Slides: FY 2024

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 9:10 AM EDT - 1 year ago

Vera Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

Sep 3, 2024, 7:49 AM EDT - 1 year ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Vera Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Quarterly report: Q2 2024

Vera Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q2 2024

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 11, 2024, 4:01 PM EDT - 2 years ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vera Therapeutics Slides: Corporate Presentation

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Slides: Corporate Presentation

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 28, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 25, 2024, 9:40 AM EDT - 2 years ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Vera Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Quarterly report: Q1 2024

Vera Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q1 2024

Vera Therapeutics Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Proxy statement: Proxy Filing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Proxy statement: Proxy Filing

Vera Therapeutics Annual report: Q4 2023

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Annual report: Q4 2023

Vera Therapeutics Earnings release: Q4 2023

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Earnings release: Q4 2023

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 20, 2024, 7:30 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vera Therapeutics Transcript: 44th Annual TD Cowen Health Care Conference

Mar 4, 2024, 2:10 PM EST - 2 years ago

Vera Therapeutics Transcript: 44th Annual TD Cowen Health Care Conference

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 28, 2024, 4:20 PM EST - 2 years ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Vera Therapeutics Slides: Corporate Presentation

Feb 14, 2024, 2:00 AM EST - 2 years ago

Vera Therapeutics Slides: Corporate Presentation

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 2, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Feb 1, 2024, 4:05 PM EST - 2 years ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 2 years ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Vera Therapeutics Transcript: R&D Day 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Transcript: R&D Day 2024

Vera Therapeutics Press release: FY 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Press release: FY 2024

Vera Therapeutics Slides: FY 2024

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Slides: FY 2024

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 25, 2024, 6:30 AM EST - 2 years ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Vera Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 6:00 PM EST - 2 years ago

Vera Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Jan 8, 2024, 8:01 AM EST - 2 years ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 27, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 9, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

flamingojack
flamingojack Jul. 4 at 12:57 PM
$VERA Claude, Gemini, Grok, and ChatGPT all state we’re setup for a squeeze.
1 · Reply
The_Beginner
The_Beginner Jul. 3 at 8:54 PM
$VERA how come there is not more excitment here with fda result the coming week?
3 · Reply
Oscarca
Oscarca Jul. 3 at 6:13 PM
$CELC It’s going to be one exciting July with both $CELC and $VERA
0 · Reply
Oscarca
Oscarca Jul. 3 at 5:09 PM
$VERA Double fireworks Vera and 4th of July 🚀
0 · Reply
flamingojack
flamingojack Jul. 3 at 4:54 PM
$VERA options data pulled from the last trading session.
0 · Reply
flamingojack
flamingojack Jul. 3 at 4:29 PM
$VERA lots of good stuff in this article. Very excited for the future of atacicept (and my portfolio) https://finance.yahoo.com/healthcare/articles/fda-progress-could-send-biotech-134034059.html?.tsrc=ios&guccounter=1
0 · Reply
treadingw4ter
treadingw4ter Jul. 2 at 9:03 PM
$VERA Last PDUFA I held through was GRCE. Having flashbacks. Worth trimming into strength on this, or do we have 𝘵𝘩𝘢𝘵 much conviction?
2 · Reply
RandomInvestor777
RandomInvestor777 Jul. 2 at 8:25 PM
$VERA btw wasn't PIONEER data supposed to be out by now? they said Q2...
1 · Reply
oneg
oneg Jul. 2 at 8:13 PM
$VERA Only two working days left before the final decision.
2 · Reply
Xavier75
Xavier75 Jul. 2 at 7:48 PM
$VERA
0 · Reply
MZ2X
MZ2X Jul. 2 at 7:36 PM
$VERA great recovery
0 · Reply
Lolusa
Lolusa Jul. 2 at 7:11 PM
$VERA hmmmmmmm
2 · Reply
RandomInvestor777
RandomInvestor777 Jul. 2 at 6:51 PM
$VERA has any analyst talked about the upside on fda approval? downside is probably 40%-60%. but not sure of the upside considering its expected to be approved 90% PoS
2 · Reply
kdeanmoore
kdeanmoore Jul. 2 at 6:46 PM
$VERA Well... Now we know where bottom is, I about shit myself when I opened up a browser and saw 38!!! Thats a big hit if one owns a few thousand shares! But hopefully we recover most of this by the close. Fingers crossed... Had I had a decent stop in at 42 I could have bought alot of shares at 38, I knew better but didn't use one.
2 · Reply
Oscarca
Oscarca Jul. 2 at 5:20 PM
$VERA Will bounce back at probably settle at -3% at the end of the day
1 · Reply
MZ2X
MZ2X Jul. 2 at 5:20 PM
$VERA buying in for pdufa here
0 · Reply
Oscarca
Oscarca Jul. 2 at 5:18 PM
$VERA accumulating
0 · Reply
greensmell
greensmell Jul. 2 at 4:48 PM
$VERA This should actually trade 50+ with comp data released yesterday. No reason this should trade red today. Good time to add.
1 · Reply
Jyoudoit
Jyoudoit Jul. 2 at 4:36 PM
$VERA Genuine question here: with today’s Otsuka two-year data, how do people see Vera’s chances of still outperforming or differentiating? I’m trying to understand the current setup properly, not looking for hype either way. If anyone has a realistic take on eGFR data and commercial positioning, would really appreciate it. Thanks.
3 · Reply
Windy007
Windy007 Jul. 2 at 4:34 PM
$VERA Question for board. Voycact's results issued last night showed a placebo adjusted reduction of proteinurea of 51%. Atacicept" reduction was 41.8%. I think this explains the hit. Am I missing something?
2 · Reply
UVXYtrading
UVXYtrading Jul. 2 at 4:17 PM
$VERA added more here! There is no news. PDUFA approval is still July 7!
1 · Reply
diggs24
diggs24 Jul. 2 at 4:04 PM
$VERA Grabbed a couple hundred here.
0 · Reply